Our treatments have the potential to save lives, our pipeline aims to protect futures and our commitment aspires to elevate what can be achieved in oncology.
- Pre-Clinical Pre-CN
- Ph 1
- Ph 2
- Ph 3
Indication: Relapsed pLGG
Progress: Phase 2
Clinical Trial: Enrolling (FIREFLY-1) 1
Indication: Frontline pLGG
Progress: Phase 3
Clinical Trial: Enrolling (FIREFLY-2)
Indication: MAPK-altered solid tumors 3*
Progress: Phase 1
Clinical Trial: Enrolling (FIRELIGHT-1)4
Indication: Pediatric and adult cancers 5*
1 FIREFLY-1 is a pivotal Phase 2 trial expected to support registration.
2 DAY101 adult monotherapy Phase 1 dose escalation and expansion trial previously completed.
3 Pimasertib Phase 1 dose escalation and expansion trial previously completed.
4 Trial in combination with DAY101.
5 Research collaboration and license agreement with Sprint Bioscience for exclusive worldwide rights to a research-stage program targeting VRK1.
* Includes patients ≥12 years of age.